Magnetic Tides

Magnetic Tides operates in neurotechnology and biotechnology, developing kTMP, a non-invasive brain stimulation method. Its stated technical distinction is the use of frequency-specific magnetic fields intended to modulate neural activity with spatial and frequency specificity. This gives the company a defined approach within the broader neuromodulation field, while its research focus on stroke recovery and conditions including anhedonia spans rehabilitation and mental health applications. Its market position is better understood through its technical focus and stage: a small, private company founded in 2019, with an employee range of 1–10 and one recorded non-equity assistance round from MedTech Innovator in 2026. The 2025 UCSF Rosenman RISE cohort is an additional signal of participation in a health-innovation program, not evidence by itself of clinical validation or market traction. Key factors for assessing differentiation against established brain-stimulation approaches will include comparative efficacy, safety, treatment practicality, regulatory progress, and reproducibility.

Magnetic Tides was founded in 2019 and is developing kTMP, a non-invasive brain stimulation method, with stated research interests spanning stroke recovery, neurological and psychiatric conditions, and anhedonia. Ludovica Labruna is listed as founder and CEO, with her leadership role beginning in 2021. A notable external milestone came on Apr 30, 2025, when the company was included in the 2025 UCSF Rosenman RISE Program class. On May 27, 2026, it received non-equity assistance from MedTech Innovator; no amount was disclosed, and the assistance should not be interpreted as a priced equity round. Together, these milestones indicate program participation and support for development, but they do not establish clinical validation, regulatory clearance, or revenue growth. These signals suggest a lean operating footprint rather than visible workforce expansion. The main inflection points to watch are publication of clinical evidence, progression through regulatory steps, expansion of research or healthcare partnerships, and any move toward product deployment.